3-Hydroxy-3-methylglutaryl-coenzyme A reductase mRNA in Alzheimer and control brain

被引：16

作者：

Yasojima, K ^{[1
]}

McGeer, EG ^{[1
]}

McGeer, PL ^{[1
]}

机构：

[1] Univ British Columbia, Dept Psychiat, Kinsmen Lab Neurol Res, Vancouver, BC V6T 1Z3, Canada

来源：

NEUROREPORT | 2001年 / 12卷 / 13期

关键词：

ApoE; cholesterol synthesis; heart; kidney; liver; spleen; statins;

D O I：

10.1097/00001756-200109170-00036

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Statins are widely used pharmaceutical agents which lower plasma cholesterol by inhibiting the rate controlling enzyme 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase. One epidemiological study suggests that statin therapy may provide protection against Alzheimer disease (AD). The aim of the present study was to determine the relative expression of HMG-CoA reductase nnRNAs in various areas of brain as well as in peripheral organs and to compare values in AD and control cases. High levels of the mRNA were found in all areas of brain but no obvious differences were found between AD and controls. We conclude that brain has a robust capacity to synthesize cholesterol which appears to be unaffected by AD pathology. NeuroReport 12:2935-2938 (C) 2001 Lippincott Williams & Wilkins.

引用

页码：2935 / 2938

页数：4

共 50 条

[21] Tacrolimus and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: An interaction study in CYP3A5 non-expressors, renal transplant recipients
Katsakiori, Paraskevi F.
Papapetrou, Eirini P.
Goumenos, Dimitrios S.
Nikiforidis, George C.
Flordellis, Christodoulos S.
INDIAN JOURNAL OF PHARMACOLOGY, 2011, 43 (04) : 385 - 388
[22] 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (pravastatin) inhibits endothelial cell proliferation dependent on G1 cell cycle arrest
Asakage, M
Tsuno, NH
Kitayama, J
Kawai, K
Okaji, Y
Yazawa, K
Kaisaki, S
Takahashi, K
Nagawa, H
ANTI-CANCER DRUGS, 2004, 15 (06) : 625 - 632
[23] 3-hydroxy 3-methylglutaryl coenzyme a reductase inhibition impairs muscle regeneration
Trapani, Laura
Segatto, Marco
La Rosa, Piergiorgio
Fanelli, Francesca
Moreno, Sandra
Marino, Maria
Pallottini, Valentina
JOURNAL OF CELLULAR BIOCHEMISTRY, 2012, 113 (06) : 2057 - 2063
[24] A novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) splice variant with an alternative exon 1 potentially encoding an extended N-terminus
Stormo, Camilla
Kringen, Marianne K.
Grimholt, Runa M.
Berg, Jens P.
Piehler, Armin P.
BMC MOLECULAR BIOLOGY, 2012, 13
[25] The role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) in modern rheumatology
Kotyla, Przemyslaw
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2010, 2 (05) : 257 - 269
[26] Hypercholesterolemia and 3-hydroxy-3-methylglutaryl coenzyme A reductase regulation in aged female rats
Trapani, Laura
Violo, Francesca
Pallottini, Valentina
EXPERIMENTAL GERONTOLOGY, 2010, 45 (02) : 119 - 128
[27] 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (fluvastatin) decreases inflammatory angiogenesis in mice
Araujo, Fernanda A.
Rocha, Monaliza A.
Capettini, Luciano S. A.
Campos, Paula P.
Ferreira, Monica A. N. D.
Lemos, Virginia S.
Andrade, Silvia P.
APMIS, 2013, 121 (05) : 422 - 430
[28] Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on coronary endothelial function
Wassmann, S
Faul, A
Hennen, B
Scheller, B
Böhm, M
Nickenig, G
CIRCULATION RESEARCH, 2003, 93 (09) : E98 - E103
[29] CRILVASTATIN, A NEW 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE INHIBITOR, INHIBITS CHOLESTEROL ABSORPTION IN GENETICALLY HYPERCHOLESTEROLEMIC RATS
HAJRI, T
FEREZOU, J
LARUELLE, C
LUTTON, C
EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 286 (02) : 131 - 136
[30] 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Regulation by Antioxidant Compounds: New Therapeutic Tools for Hypercholesterolemia?
Trapani, L.
Segatto, M.
Incerpi, S.
Pallottini, V.
CURRENT MOLECULAR MEDICINE, 2011, 11 (09) : 790 - 797

← 1 2 3 4 5 →